POSB127 Cost-Comparison of HBA1C reduction with Gliclazide-Modified Release or Sitaglipltin in Patients with Uncontrolled Type 2 Diabetes after Metformin Monotherapy

Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.400
https://www.valueinhealthjournal.com/article/S1098-3015(21)02195-1/fulltext
Section Title :
Section Order : 11178
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02195-1&doi=10.1016/j.jval.2021.11.400
HEOR Topics :
Tags :
Regions :